Your session is about to expire
← Back to Search
BMS-986322 + Rosuvastatin + Metformin + Methotrexate for Healthy Subjects
Study Summary
This trial will study how drugs interact when taken together to see if they work better than when taken alone.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is this research initiative recruiting participants who are 50 years of age or older?
"To qualify for this study, the participant must be above 18 years of age but below 60."
To what degree is the combination of Methotrexate + BMS-986322 + Leucovorin deemed safe for human use?
"Limited clinical data exists to support the safety and effectiveness of Methotrexate + BMS-986322 + Leucovorin, thus it was awarded a score of 1."
How large is the cohort of participants in this research initiative?
"Affirmative. Clinicaltrials.gov specifies that the recruitment process for this clinical trial is ongoing, having been initially posted on November 11th 2022 and last updated September 7th 2023. The research team aims to enlist 76 participants at 1 medical facility."
Does this investigation still have room for enrolment?
"Affirmative. Per the information on clinicaltrials.gov, this medical trial is actively recruiting participants since its initial post on November 11th 2022 and last update of September 7th 2023. 76 individuals need to be recruited over one site for completion of the study."
Are there any specific requirements for participating in this clinical experiment?
"This clinical trial seeks 76 individuals, aged between 18 and 60 who are judged to be in optimal health. To take part they must meet a number of conditions, including having a BMI from 18-30kg/m^2 and body weight over 50 kg for males or 45 kg for females. Additionally female participants may not donate oocytes during the experiment's duration or at least 5 days after their final dose of medication is administered."
Share this study with friends
Copy Link
Messenger